Search the Newsreel

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …

NewMarket declares $3.00 quarterly dividend, payable Oct. 1

NewMarket Corporation (NYSE:NEU) has announced a quarterly dividend of $3.00 per share on its common stock. The dividend is scheduled to be paid on October 1, 2026, to shareholders of record as of September 15, 2026. NewMarket operates as a holding company with subsidiaries …

NewMarket Corporation Announces $3.00 Quarterly Dividend Payment for October 2026

NewMarket Corporation (NYSE: NEU) has declared a quarterly cash dividend of $3.00 per common share. The dividend is payable on October 1, 2026, to shareholders of record as of September 15, 2026. This announcement was made via a Form 8-K filing with the SEC …

Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants

Farallon Capital Management, L.L.C., along with associated investment partnerships and individuals, has disclosed a 9.7% beneficial ownership in Minerva Neurosciences (NERV). This stake comprises 4,730,000 shares of common stock, including 2,365,000 directly held common shares and shares acquirable through 5,000 Preferred Tranche A Warrants. …

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript

NewMarket Corporation Announces Quarterly Dividend

RICHMOND, Va., August 13, 2026--(BUSINESS WIRE)--The Board of Directors of NewMarket Corporation (NYSE: NEU) declared a quarterly dividend in the amount of $3.00 per share on the common stock of the Corporation. The dividend is payable October 1, 2026, to NewMarket shareholders of record …

ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D

ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences announced its Q2 2026 financial results, ending the quarter with $53.4 million in cash, expected to fund operations through 2027. The company also provided positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310 in early …

ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary

ProMIS Neurosciences Inc. reported a net loss of $(11.73)M for Q2 2026, with a diluted loss per share of $(1.28), an increase in net loss compared to Q2 2025 but an improvement in diluted EPS. The company generated no product revenue. Key highlights include …

Alto Neuroscience stock hits all-time high at 32.74 USD

Alto Neuroscience Inc. (ANRO) stock has reached an all-time high of $32.74, marking a 906.09% increase over the past year. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently announced a stock offering to raise $100 million, received a reiterated …

Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% Higher - Should You Buy?

Wedbush Adjusts Price Target on Alto Neuroscience to $26 From $24, Keeps Neutral Rating

Wedbush has increased its price target for Alto Neuroscience from $24 to $26, while maintaining a Neutral rating on the stock. The article also briefly mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and a quarterly loss …

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

Three analysts have issued bullish sentiments on healthcare companies Immunic (IMUX), Legend Biotech (LEGN), and Sagimet Biosciences, Inc. Class A (SGMT). William Blair reiterated a Buy rating on Immunic, H.C. Wainwright reiterated a Buy on Legend Biotech with a $65.00 price target, and Wedbush …

Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat

Alto Neuroscience (NYSE:ANRO) shares rose 8% after reporting a quarterly loss of $0.65 per share, surpassing the consensus estimate of a $0.73 loss. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $36.62, and institutional investors like Commodore Capital and …

Die Wacker-Neuson-Aktie bestätigt Prognose nach starkem Halbjahr

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Earnings call transcript: NeuroOne Medical posts Q3 2026 revenue growth as shares fall

NeuroOne Medical Technologies reported a 16% year-over-year increase in Q3 2026 product revenue, reaching $2.0 million, driven by stronger sales of its OneRF brain ablation products and a 43% jump in orders. Despite revenue growth and improved gross margins, the company's net loss widened …

Is NeuroOne Medical Technologies Corp (NMTC) Positioned for Grow

NeuroOne Medical Technologies (NASDAQ: NMTC) posts larger loss and flags going concern risk

NeuroOne Medical Technologies (NMTC) reported a deeper net loss of $2.01 million for Q3 2026 and $5.83 million for the nine months ended June 30, 2026, significantly larger than the previous year. The company's cash and cash equivalents dwindled to $2.05 million, leading management …

Form 8K Neuroone Medical Technologies Corp For: 13 August By Investing.com

This article announces that Neuroone Medical Technologies Corp filed a Form 8K on August 13. It includes the company's stock symbol (NMTC) and its current performance. The content primarily serves as a placeholder for the filing and does not provide further details about the …

NeuroOne posts Q3 FY2026 revenue up 16% to $2.0M; gross margin expands to 59.9%

NeuroOne (NMTC) reported a 16% increase in Q3 FY2026 product revenue to $1.97 million, with product gross margin expanding to 59.9%. Despite a net loss of $2.01 million, the company secured $2.7 million in new product orders and achieved ISO 13485:2016 certification. Significant progress …

NeuroOne Medical Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne Medical Technologies Corporation reported strong fiscal Q3 2026 financial results, with product revenue increasing 16% year-over-year to $2.0 million and gross margins expanding to 59.9%. The company also announced $2.7 million in new product orders, received ISO 13485 Certification for international expansion, and …

Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

Wacker Neuson Group veröffentlicht Halbjahresbericht 2026 und bestätigt angehobene Jahresprognose

NeuroPace (NPCE) Stock Price Faces Flat Revenue And Lingering Losses

Alto Neuroscience Q2 EPS beats estimates; completes $100M financing

Alto Neuroscience (NYSE: ANRO) reported a Q2 2026 EPS of $(0.65), exceeding analyst estimates of $(0.73). The company also completed a $100 million financing round in July 2026, boosting its pro forma cash position to approximately $338 million, which is expected to fund operations …

ClearPoint Neuro (CLPT): MAK Capital group discloses 7.8% ownership in 13G/A

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have filed a Schedule 13G/A, disclosing a collective beneficial ownership of 2,375,861 shares of ClearPoint Neuro, Inc. (CLPT) common stock. This represents 7.8% of the company's outstanding shares as of June 30, …

Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges

Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, widening from the previous year, primarily due to increased R&D expenses which surged to $22.1 million. Despite the loss, the company significantly strengthened its balance sheet, increasing cash and cash equivalents …

Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role

Minerva Neurosciences (NERV) has promoted Anthony Aliquo to Chief Accounting Officer and principal accounting officer, effective August 10, 2026. This move includes an increase in his annual base salary to $296,696 and a performance bonus target of 35%. Frederick Ahlholm remains the Chief Financial …

NeuroPace Q2 Earnings Call Highlights

NeuroPace reported strong Q2 revenue growth driven by its RNS System for adult focal epilepsy, leading to a raised full-year revenue and adjusted EBITDA outlook. The company is also engaging with the FDA regarding expanding the RNS System's indication to idiopathic generalized epilepsy (IGE), …

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet …